Our latest articles

Vantage logo

Novartis trims its pipeline

Discontinuations for branaplam, iptacopan and Piqray could increase pipeline scepticism, but more pruning is coming.

Vantage logo

Astrazeneca gets personal

A collaboration this week with the blood testing specialist Capitainer underlines the big pharma’s ambition to have a diagnostic linked with every pipeline project.

Vantage logo

The end of the Humira era

With $219bn in accumulated sales the Abbvie mega-blockbuster is biopharma’s best-selling drug. Can Keytruda do better?

Vantage logo
Independent, data-driven daily news and analysis on pharma, biotech and medtech.